clinical trial · NCT04750252
Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint
Akan Biosciences, LLC·phase2·not yet recruiting·n = 20
Osteo Arthritis KneeStroMel
brief summary
The aim of this trial is to evaluate the safety and tolerability of autologous StroMel™ for the treatment of moderate to severe OA of the knee joint.
started
Oct 1, 2025
primary completion
Aug 31, 2027
completion
Aug 31, 2027
last updated
Jan 29, 2025
official title
An Open Label Study to Evaluate Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol